ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KROS vs SIGA // EV/EBITDA & P/E VALUATION

Keros Therapeutics Inc. (NASDAQ) VS. SIGA Technologies Inc. (NASDAQ) • 15-METRIC TALLY: KROS 6 — SIGA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KROS VS. SIGA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KROS SIGA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 68.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% 42.70% +42.30 KROS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 4.8x — TIE /valuation <GO>
Free Cash Flow Yield — 19.03% — TIE /fcf-yield <GO>
Operating Margin 27.70% 25.10% +2.60 KROS /operating-margins <GO>
Net Profit Margin 35.70% 24.60% +11.10 KROS /net-margins <GO>
Revenue Growth (YoY) 180.00% -31.80% +211.80 KROS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.31 8.22 -3.91 SIGA /balance-sheet <GO>
Piotroski F-Score Quality 8/9 6/9 +2.00 KROS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.6 36.7 +3.88 KROS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 9.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $225.2M $228.5M -$3.2M SIGA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KROS REV SIGA REV KROS GROSS % SIGA GROSS % KROS FCF SIGA FCF
FY 2025 $244.1M $94.6M — 68.6% $106.0M $43.5M
FY 2024 $3.5M $138.7M — 77.4% -$162.8M $48.8M
FY 2023 $151.0K $139.9M — — -$124.5M $94.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KROS // BETA —
SIGA // BETA —